ANET Electrosurgery Applicator Pilot Evaluation Study
Evaluate the preliminary safety and performance of the Electrosurgery Applicator (ANET device) during and after bronchoscopic ablation of a target pulmonary nodule/tumor.
Checked against the public recordLast updated Apr 3, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Device Feasibility
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Olympus Corporation of the Americas
- Interventions being studied
- Device: RF Ablation
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. Subject with Stage I or Stage II primary lung cancer or metastatic lung tumor 2. Pathological proof of target nodule/tumor type and malignancy 3. Target nodule/tumor which can be accessed via EBUS bronchoscopy 4. Resection/surgical candidate 5. Participants must be at least 18 years old and able to provide consent Exclusion criteria: 1. Subjects in whom flexible bronchoscopy is contraindicated 2. Target nodule \< 1.0 cm 3. Prior radiation or neo adjuvant chemotherapy of the target nodule/tumor 4. Any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives 5. Pacemaker, implantable cardioverter, or other electronic implantable device
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Beth Israel Deaconess Medical CenterBoston, Massachusetts
- Duke University Medical CenterDurham, North Carolina
- UT MD Anderson Cancer CenterHouston, Texas
- Toronto General HospitalToronto, Ontario
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 3, 2024. Always confirm current availability with the study team.